RAPT Therapeutics, Inc. (RAPT) Cash & Current Investments (2020 - 2024)
RAPT Therapeutics' Cash & Current Investments history spans 5 years, with the latest figure at $97.8 million for Q3 2024.
- For Q3 2024, Cash & Current Investments fell 47.08% year-over-year to $97.8 million; the TTM value through Sep 2024 reached $97.8 million, down 47.08%, while the annual FY2023 figure was $158.9 million, 36.22% down from the prior year.
- Cash & Current Investments for Q3 2024 was $97.8 million at RAPT Therapeutics, down from $114.8 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $249.1 million in Q4 2022 and bottomed at $97.8 million in Q3 2024.
- The 5-year median for Cash & Current Investments is $173.0 million (2022), against an average of $167.7 million.
- The largest annual shift saw Cash & Current Investments surged 75.81% in 2022 before it crashed 47.08% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $111.5 million in 2020, then soared by 70.08% to $189.7 million in 2021, then soared by 31.33% to $249.1 million in 2022, then crashed by 36.22% to $158.9 million in 2023, then tumbled by 38.45% to $97.8 million in 2024.
- Per Business Quant, the three most recent readings for RAPT's Cash & Current Investments are $97.8 million (Q3 2024), $114.8 million (Q2 2024), and $141.6 million (Q1 2024).